December 16, 2014
There are currently two analysts that we track that cover the stock. Of those two, one has a Buy rating, one has a Hold rating. On a consensus basis this yields a score of 2.50 and a Buy. The combined price objective of these covering analysts is $11.00, which represents a 175.68% upside difference to the last closing price.
The most recent analyst activity consisted of Mizuho initiated coverage with a Buy stance on the company. Mizuho has a price target of $11.00 which represents an upside of 175.68% from the last closing price. On the date of the report, the stock closed at $4.85.
Another research firm weighing in recently was Piper Jaffray who upgraded their rating on the stock.
You should have done a 30 day Wash Sale at the end of November. You would not miss any run up if you bought an equal amount of shares or doubled up and then sell the first shares 31 days later.
If history repeats itself, oil and gas company stocks will rebound with increased prices for energy over time and be back up to new heights in two years. With Magnum Hunter Resources that means $10.00 a share and a 300% gain.
Look for a resolution to the situation as opposed to a further standoff.
It is common to write a check for $1 to pay for something that is of a much higher value when it exchanges hands in a deal that benefits both parties.
There is irrational hysteria with talk of $30 a barrel oil and unlimited news of predictions regarding bankruptcy energy valuations. There has to be an underlying story here that will be revealed in retrospect regarding trader manipulation.
Reynolds American Inc. is launching a cigarette that heats tobacco rather than burning it, hoping to capitalize on the growing appetite for alternatives to traditional smokes.
The nation's second-biggest tobacco company said Monday that it will begin selling Revo — a cigarette that uses a carbon tip that heats tobacco after being lit — in Wisconsin in February 2015. Reynolds said the cigarette is a "repositioning" of its Eclipse product first launched in the mid-1990s with minimal success.
The surging e-cigarette or vapor industry has reinvigorated the interest for cigarette alternatives, including products like Revo and its predecessor Eclipse that smokers once considered foreign. Even though the products left no lingering odor and didn't produce ashes, they tasted different than cigarettes and were more difficult to use. Eclipse had remained in limited distribution and is one of the top-selling brands in the cafeteria at Reynolds' headquarters in Winston-Salem, North Carolina.
"Heat-not-burn technology was 20 years ahead of when consumers were ready for it. It needed the mass presence of vapor products to open up an experience-base that smokers understood," said J. Brice O'Brien, head of consumer marketing for the maker of Camel and Pall Mall cigarettes. "The smoker could only compare heat-not-burn to a combustible and it lost every time. That's no longer the case."
Revo is a "modern take on the classic cigarette" that — unlike popular e-cigarettes that use liquid nicotine — contains real tobacco, which could make them more attractive to cigarette smokers, O'Brien said.
Not sure it was the right thing to do, but I bought in the $1's and have a considerable gain. Picked up a shale oil and natural gas company stock that has plummeted, Magnum Hunter Resources.
GLTA ACAD Longs.
The stock price skyrockets at the open to $2.00 a share and trades at $10 with an unprecedented surprise unauthorized 1:5 Reverse Split?
AEterna Zentaris PT Lifted to $6 at Maxim Group
redisnI teertS (Backwards)
Maxim Group analyst Jason Kolbert reiterated a Buy and bumped his price target on AEterna Zentaris (NASDAQ: AEZS) price target of $6.00 (from $5.00) as the company is ready for launch.
Kolbert commented, "AEterna reported $42M in cash with only a modest burn of $9.8M. The company continues its "Resource Optimization Program" with efforts to streamline R&D activities and increase commercial operations and flexibility. The effort to optimize the company as a commercial specialty pharma company is expected to result in 31 employee terminations. Severance packages added $1.6M to this quarter's R&D expense. AEterna also issued 1.6M common shares as part of its May 2014 ATM program, though dilution is minimal, with 59M shares outstanding."
He added, "The co-promotion of Estrogel and Macrilen will begin with AEterna's 20 reps getting out in the field beginning November 17, 2014, which, combined with ASCEND reps, brings the total to 53. This is just in time for the final review of the Macrilen NDA (PDUFA November 5, 2014)."
"Site initiation (120 sites) is now complete for the current ZoptEC (Zoptarelin doxorubicin in endometrial cancer) phase III trials. All sites are operational, and 300 of the expected 500 patients have been enrolled."